Tositumomab

From Wikipedia, the free encyclopedia

Tositumomab?
Therapeutic monoclonal antibody
Source Mouse
Target CD20
Identifiers
CAS number 192391-48-3
ATC code V10XA53
PubChem  ?
DrugBank BTD00085
Chemical data
Formula C6416H9874N1688O1987S44 
Mol. mass 143859.7 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to 131I. 131I emits both beta and gamma radiation and decays with a half-life of 8 days.

Clinical trials have established the efficacy of tositumomab in patients with relapsed or chemotherapy/rituxan refractory follicular lymphoma.

The drug was developed by Dr. Mark Kaminski and Dr. Richard Wahl. It is manufactured by Corixa. It sells in the U.S. under the trade name Bexxar.

There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.[1]

[edit] References

  1. ^ Jacene HA, Filice R, Kasecamp W, Wahl RL (2007). "Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice". J. Nucl. Med. 48 (11): 1767–76. doi:10.2967/jnumed.107.043489. PMID 17942813. 
v • d • e
Mouse monoclonal antibodies ("-o-")
"govo" (ovarian tumor)
"limo" (immune system)
"tumo" (miscellaneous tumor)
"leso" (infectious lesions)
"ciro" (cardiovascular)
"pro" (prostate tumor)
"baco" (bacterial)
"colo" (colonic tumor)
v • d • e
Radiopharmaceuticals (V09-V10)
CI CD20 Antibodies
Tositumomab - Ibritumomab tiuxetan
Other
 This medical treatment article is a stub. You can help Wikipedia by expanding it.